TABLE 1.

In vitro activity of telavancin against resistant staphylococci, streptococci, and enterococci

Organism (no. tested) and antibioticMIC (μg/ml)g% Susceptiblea
Range50%90%
S. aureus, methicillin resistant (98)
    Telavancin0.06-10.250.5
    Vancomycin0.25-20.51100
    Teicoplanin0.25-40.51100
    Ciprofloxacin≤0.06->881632
    Daptomycin0.12->10.250.598
    Linezolid1-82498
    Quinupristin-dalfopristin≤0.12-0.50.250.599
    Gentamicin≤0.06->160.5297
    Erythromycin0.5->16>16>162
    Telithromycin0.06->80.251683
    Trimethoprim-sulfamethoxazoleb≤0.5-4≤0.5≤0.599
S. epidermidis, methicillin resistant (74)
    Telavancin0.25-10.51
    Vancomycin0.5-422100
    Teicoplanin0.25-1681681
    Ciprofloxacin≤0.12->84>828
    Daptomycin0.25-10.51100
    Linezolid≤0.5-411100
    Quinupristin-dalfopristin≤0.12-40.25293
    Gentamicin≤0.06->1616>1635
    Erythromycin≤0.12->16>16>1615
    Telithromycin0.06->80.5>843
    Trimethoprim-sulfamethoxazoleb≤0.5->4>4>437
CoNS, methicillin resistant (17)c
    Telavancin0.06-10.51
    Vancomycin0.25-422100
    Teicoplanin≤0.12-3243288
    Ciprofloxacin≤0.06->8>8>835
    Daptomycin0.12-10.251100
    Linezolid0.5-212100
    Quinupristin-dalfopristin≤0.12-10.250.5100
    Gentamicin≤0.06->1616>1629
    Erythromycin≤0.12->16>16>1618
    Telithromycin0.12->8>8>829
    Trimethoprim-sulfamethoxazoleb≤0.5->4>4>429
S. pneumoniae, penicillin intermediate (12)
    Telavancin0.004-0.120.0150.06
    Vancomycin≤0.06-0.50.250.5100
    Daptomycin0.06-10.120.5
    Linezolid0.5-211100
    Penicillin0.12-1110
    Clindamycin0.06->0.250.060.583
    Erythromycin0.03->1>1>142
    Telithromycin0.008-0.120.030.12100
    Trimethoprim-sulfamethoxazoleb≤0.06->4248
    Cefuroxime0.5->42417
    Ceftriaxone0.25-20.5192
    Levofloxacin0.25-80.5192
    Tetracycline≤0.06->80.12>867
S. pneumoniae, penicillin resistant (59)
    Telavancin0.008-0.120.0150.03
    Vancomycin0.12-10.250.25100
    Daptomycin0.06-0.50.120.12
    Linezolid0.5-211100
    Penicillin2->22>20
    Clindamycin≤0.03->0.250.06>0.2576
    Erythromycin0.03->1>1>120
    Telithromycin0.004-0.50.060.5100
    Trimethoprim-sulfamethoxazoleb≤0.06->44>43
    Cefuroxime1->4>4>42
    Ceftriaxone0.5->41273
    Levofloxacin≤0.12->80.5197
    Tetracycline≤0.06->8>8>841
MDRSP (60)d
    Telavancin0.008-0.120.0150.03
    Vancomycin0.12-10.250.25100
    Daptomycin0.06-0.50.120.12
    Linezolid0.5-211100
    Penicillin1->22>20
    Clindamycin≤0.03->0.250.06>0.2573
    Erythromycin0.03->1>1>113
    Telithromycin0.004-0.50.060.5100
    Trimethoprim-sulfamethoxazoleb≤0.06->44>43
    Cefuroxime1->4>4>42
    Ceftriaxone0.5->41277
    Levofloxacin≤0.12->80.5195
    Tetracycline≤0.06->8>8>837
S. pyogenes, group A (122)
    Telavancin≤0.001-0.120.030.06
    Vancomycin≤0.06->10.250.598
    Daptomycin≤0.03-1≤0.030.25100
    Linezolid≤0.012->21198
    Penicillin≤0.06->2≤0.06≤0.0693
    Clindamycin≤0.03->0.25≤0.030.0698
    Erythromycin≤0.015->10.03>189
    Telithromycin0.004-10.0150.015
    Trimethoprim-sulfamethoxazoleb≤0.06-4≤0.060.12
    Cefuroxime≤0.12->4≤0.120.25
    Ceftriaxone≤0.015->4≤0.0150.1292
    Levofloxacin≤0.12->80.5198
    Tetracycline≤0.06->80.12489
S. agalactiae, group B (81)
    Telavancin0.03-0.120.060.06
    Vancomycin0.25-10.250.5100
    Daptomycin0.06-0.50.250.25100
    Linezolid0.25-211100
    Penicillin≤0.06->2≤0.06≤0.0696
    Clindamycin≤0.03->0.250.06>0.2586
    Erythromycin≤0.015->10.06>162
    Telithromycin0.004-0.50.0150.25
    Trimethoprim-sulfamethoxazoleb≤0.06-20.120.12
    Cefuroxime≤ 0.12->4≤0.12≤0.12
    Ceftriaxone0.03->40.060.0696
    Levofloxacin≤0.12->80.5199
    Tetracycline≤0.06->8>8>816
Viridans group streptococci (8)f
    Telavancin0.015-0.06N/AeN/A
    Vancomycin0.25-1N/AN/A100
    Daptomycin0.25-1N/AN/A100
    Linezolid0.5-2N/AN/A100
    Penicillin≤0.06->2N/AN/A62
    Clindamycin≤0.03->0.25N/AN/A88
    Erythromycin≤0.015->1N/AN/A63
    Telithromycin0.004-0.25N/AN/A
    Trimethoprim-sulfamethoxazoleb≤0.06-4N/AN/A
    Cefuroxime≤0.12->4N/AN/A
    Ceftriaxone0.03->4N/AN/A75
    Levofloxacin≤0.12-1N/AN/A100
    Tetracycline0.12->8N/AN/A75
E. faecalis, vancomycin resistant, VanA (21)
    Telavancin4-32816
    Vancomycin128->512512>5120
    Teicoplanin32->12864>1280
    Ampicillin≤0.25-12816481
    Ciprofloxacin0.25->32>32>3214
    Daptomycin0.5-412100
    Linezolid1-212100
E. faecalis, vancomycin resistant, VanB (5)
    Telavancin0.25-1N/AN/A
    Vancomycin32-256N/AN/A0
    Teicoplanin0.5-1N/AN/A100
    Ampicillin≤0.25-64N/AN/A60
    Ciprofloxacin32->32N/AN/A0
    Daptomycin0.5-4N/AN/A100
    Linezolid0.5-2N/AN/A100
E. faecium, vancomycin resistant, VanA (159)
    Telavancin2-16816
    Vancomycin64->512512>5120
    Teicoplanin16->12864>1280
    Ampicillin16->128641280
    Ciprofloxacin2->32>32>320
    Daptomycin0.5-82498
    Linezolid0.25-322299
    Quinupristin-dalfopristin0.25-160.5198
E. faecium, vancomycin resistant, VanB (27)
    Telavancin0.06-20.52
    Vancomycin32->512512>5120
    Teicoplanin0.25-40.51100
    Ampicillin0.5-128646422
    Ciprofloxacin8->32>32>320
    Daptomycin0.25-82493
    Linezolid0.5-42296
    Quinupristin-dalfopristin0.5->321867
  • a MIC interpretive criteria from CLSI document M100-S17 used for determination of % Susceptible (—, breakpoint not available) (4).

  • b MICs reported based on concentration of trimethoprim.

  • c Includes two isolates of S. auricularis, one S. capitis, five S. haemolyticus, eight S. hominis subsp. novobiosepticus, and one S. saprophyticus.

  • d Multidrug-resistant S. pneumoniae.

  • e For MIC50 and MIC90, N/A indicates that the sample size was insufficient to calculate.

  • f Includes three isolates of S. mitis, two S. intermedius, and one each of S. oralis, S. constellatus, and S. viridans.

  • g Telavancin quality controls for all MIC experiments were within CLSI-defined ranges: S. aureus ATCC 29213, 0.12 to 1 μg/ml; S. pneumoniae ATCC 49619, 0.004 to 0.03 μg/ml; and E. faecalis ATCC 29212, 0.12 to 0.5 μg/ml (4).